.jpg "Sascha van Bömmel-Wegmann, PhD photo")
Integrated evidence generation Researcher
Bayer AG, Germany
Dr. Sascha van Boemmel-Wegmann currently holds the position as an Integrated Evidence Generation Researcher in the Medical Affairs & Pharmacovigilance Department at Bayer AG. In his role he is responsible for leading the development of observational research activities to answer research questions covering the entire drug lifecycle of Bayer assets. Collaborating with cross-functional teams, he has conducted retrospective observational studies focusing on real-world treatment patterns, healthcare resource utilization and drug safety/effectiveness in diverse therapeutic areas, such as chronic kidney disease, heart failure and advanced cancers, using various data sources (e.g., US, UK & German administrative claims data, electronic health records, and patient registries). Furthermore, he supports the development of integrated evidence generation strategies for Bayer assets and drives the application of innovative research designs and analytical methods in RWE generation, such as external control arm designs and data standardization strategies.
Before joining Bayer in August 2020, Sascha worked as a research consultant for the development and execution of RWE projects, observational studies and optimization of Europe-wide market access strategies at Cytel (formerly: Ingress Health GmbH).
Sascha received his professional degree in Pharmacy from the Heinrich-Heine-University in Düsseldorf, Germany, and an MS and PhD in Pharmaceutical Sciences focusing on Pharmacoepidemiology from the University of Florida Department of Pharmaceutical Outcomes and Policy.